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Introduction
The pathophysiology of non-insulin-dependent diabetes mellitus (NIDDM) results from impaired peripheral tissue sensitivity to insulin and reduction of insulin secretion. Glucose uptake in mammalian cells is mediated by a family of intrinsic membrane proteins known as facilitative glucose transporters, GLUTs (Mueckler, 1994) . GLUT4, the insulin-responsive glucose transporter, is selectively expressed in adipocytes and muscle (Bryant et al., 2002) . GLUT4 in these cells constantly recycles between the plasma membrane (PM) and intracellular storage pools (Cushm an and W ardzala, 1980) . About 90 percent of GLUT4 is sequestered intracellularly in the absence of insulin or other stimuli such as exercise (Cushman and Wardzala, 1980) . Insulin stimulates glucose uptake in these cells primarily by inducing net translocation of GLUT4 from the intracellular storage sites to the PM (Lee et al., 1999 , Lee et al., 2000b . The translocation of GLUT4 by insulin results from a cascade of signal transduction, which is composed of a series of molecules (Pessin et al., 1999) . Insulin-stimulated GLUT4 translocation and glucose uptake are mediated largely through the activation/phosphorylation of IRS-1 and its downstream effectors, such as PI3K, PDK-1, PKC-λ/ζ, and Akt2 (Saltiel and Pessin, 2002; Kanzaki and Pessin, 2003 ). An impaired GLUT4 translocation and/or insulin signaling pathway would result in insulin resistance and hyperglycemia, the primary characteristics and hallmarks of NIDDM (Watson and Pessin, 2001) .
O-GlcNAc m odification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat prim ary adipocytes
It has been known that O-GlcNAc modification of protein plays an important role in transcription, translation, nuclear transport and cytoskeletal assembly (Comer and Hart, 2000; Wells et al., 2001) . Recently, O-GlcNAc modification as well as phosphorylation/ dephosphorylation has been focused on as a main regulation mechanism of cellular signal transduction pathways. Post-translational O-GlcNAc modification on proteins is defined as the O-linked attachment of single GlcNAc moiety to specific hydroxyl groups of Ser or Thr residue (Buse et al., 2002) . Since Oglycosylation of cellular proteins via Ser/Thr takes place dynamically in various ways and the modification site is usually located near the O-phosphorylation site or sometimes at the same site, O-GlcNAc modification plays as a dynamic negative regulator against protein phosphorylation (Snow and Hart, 1998, Zachara and . Therefore, O-glycosylation and O-phosphorylation are known to participate in the modification of protein interaction and regulation of signal transduction by changing the protein reaction site through the mutual interaction (Griffith and Schmitz, 1999; Cheng et al., 2000) .
With increasing knowledge about O-GlcNAc modification as a new regulatory signal, there have been reports that abnormalities in the regulation of OGlcNAc protein modification are one of the causes in the pathogenesis of NIDDM. Marshall et al. (1991) first implicated HBP in glucose-induced insulin resistance by demonstrating a requirement for the enzyme, glutamine fructose 6-phosphate amidotransferase (GFAT). The metabolic step catalyzed by GFAT provides the necessary substrates for protein modification by O-GlcNAc. Subsequently, the infusion of glucosamine induced insulin resistance in rat by increasing uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) levels (Rossetti et al., 1995) , and the transgenic mice over-expressing GFAT also developed insulin resistance with high GFAT activity and UDP-GlcNAc levels (Hebert et al., 1996) . O-Glycosylation of several proteins was increased by the O-GlcNAc infusion in rats (Yki-Jarvinen et al., 1998) , and insulin-stimulated GLUT4 translocation to the PM was inhibited by high glucosamine treatment in rat skeletal muscle (Baron et al., 1995) . In addition to UDP-GlcNAc flux, the overexpression of O-GlcNAc transferase, an enzyme catalyzing the addition of OGlcNAc on target proteins, induced insulin resistance and hyperleptinemia in transgenic mice (McClain et al., 2002) . This result suggests that GlcNAc transferase participates in a hexosamine-dependent signaling pathway that is linked to insulin resistance and leptin production. O-GlcNAcase, an nucleocytoplasmic enzyme catalyzing removal of O-GlcNAc from proteins, is suggested as an another important modulator involved in O-GlcNAc modifications on target proteins (Dong and Hart, 1994, Wells et al., 2001) . PUGNAc, a GlcNAc analogue, potently inhibited O-GlcNAcase and induced globally elevated O-GlcNAc modification of proteins without altering N-linked glycosylation or UDP-GlcNAc levels (Haltiwanger et al., 1998) . It has been reported that the administration of PUGNAc increased cellular O-GlcNAc modification of proteins and also induced insulin resistance in 3T3-L1 adipocytes (Vosseller et al., 2002) and rat skeletal muscle (Arias et al., 2004) . These results indicate that either activation of O-GlcNAc transferase or inhibition of OGlcNAcase increases O-GlcNAc modification on proteins, and subsequently attenuates insulin signaling in peripheral tissues such as muscle and adipocytes.
Recently, Vosseller et al. (2002) demonstrated that PUGNAc induces insulin resistance by reducing insulin-stimulated phosphorylation of Akt and glycogen synthase kinase 3β (GSK3β) in 3T3-L1 adipocytes. However, Arias et al. (2004) suggest that PUGNAcinduced insulin resistance is not attributable to reduced phosphorylation of Akt or GSK3α/β in rat skeletal muscle. There is also a report that the glucosamine-induced insulin resistance is closely associated with increased O-GlcNAc modification and reduced tyrosine phosphorylation of IRS-1 and -2 in rat skeletal muscle (Patti et al., 1999) . This evidence revealed that O-GlcNAc modification on proteins by PUGNAc causes insulin resistance in muscle and adipocytes (Haltiwanger et al., 1998; Gao et al., 2000; Vosseller et al., 2002; Arias et al., 2004) . However, it is not clear how and which O-GlcNAc modification of proteins causes substantial disturbances in glucose uptake and insulin signaling, leading to insulin resistance in rat adipocytes.
In the present study, we report that treatment of PUGNAc is directly correlated with the elevation of O-GlcNAc protein modification and insulin resistance in rat primary adipocytes. Prolonged treatment of PUGNAc increased O-GlcNAc modification on several proteins and partially inhibited insulin-stimulated 2DG uptake and GLUT4 translocation. The O-GlcNAc modification of IRS-1 and Akt2 was increased by PUGNAc, accompanied by a partial reduction of insulin-stimulated phosphorylations of IRS-1 and Akt2. It is suggested that the increase of O-GlcNAc modification on insulin signal pathway intermediates, such as IRS-1 and Akt2, and the reduction in insulin-stimulated phosphorylation of IRS-1 and Akt2 are associated with the insulin resistance developed in PUGNActreated rat primary adipocytes.
M aterials and M ethods M aterials
Collagenase type I was obtained from Worthington (Lakewood, NJ). The anti-O-GlcNAc antibody designated as CTD110.6 was purchased from Covance (Princeton, NJ). Anti-GLUT4 antibody (clone 1F8) was purchased from Biogenesis Ltd. (Sandown, NH). Antibodies against IR, IRS-1, PI3K, Akt2, and PDK1 were purchased from Upstate (Lake Placid, NY). Antibody against phospho-Tyr IRS-1 was a generous gift from Dr. Pann-Gill Suh (Postech, Pohang, Korea Adipocytes preparation and subcellular fractionation All animal experiment procedures were carried out in accordance with the principles of laboratory animal care and with the approval of the ethical committee. Primary adipocytes were isolated from epididymal fat pads of male Sprague-Dawley rats (180-200 g) and stabilized as described (Liu et al., 1995; Kim et al., 2004a) . Adipocytes were cultured for 0, 3, 6 and 12 h in Krebs-Ringer's phosphate buffer (KRB: 128 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 1.25 mM MgSO4, 1 mM Na2HPO4 at pH 7.4) supplemented with 4 mM glucose in the absence or presence of PUGNAc. When insulin was used, adipocytes were treated with insulin (30 nM) for last 20 min during incubation. Subcellular membrane fractions enriched with PM and low-density microsomes (LDM) were prepared after homogenation as described (Martz et al., 1986) .
Im m unoprecipitation
For whole-cell lysates used in immunoprecipitation, adipocytes were washed twice with KRB and homogenized with 1% Nonidet P-40 buffer containing 15 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, protease inhibitors (1 mM benzamidine, 0.2 mM PMSF, 10 µM E-64, 1 µM pepstatin A and 1 µM leupeptin), phosphatase inhibitors (1 mM Na2VO4 and 100 nM okadaic acid), and 1 µM PUGNAc. Homogenates were centrifuged first at 500 g for 10 min to remove the fat cake and insoluble substances, and then the dissolved materials were centrifuged at 185,000 g for 2 h to obtain the whole-cell lysates. Immunoprecipitations with specified antibodies were performed overnight (CTD110.6) or 4 h (anti-IRS-1 and Akt2) at 4 o C according to the previously described (Vosseller et al., 2002) . Immunoprecipitation of GLUT4 was performed as described previously (Lee et al., 2000a ) with modifications. 1F8 or normal mouse IgG was coupled to Tris-acryl beads (Reacti-Gel GF2000, Pierce) at a concentration of 1.0 mg of antibody/ml of resin according to the manufacturer's instructions. The antibody-coupled beads were quenched by 2 M Tris (pH 8.0) for 1h, incubated with 2% BSA in PBS (134 mM NaCl, 2.6 mM KCl, 6.4 mM Na2HPO4, 1.46 mM KH2PO4, pH 7.4) for 2 h to prevent non-specific binding, and washed 5 times with 1 ml of PBS at room temperature. 300 µg of LDM were incubated with 90 µl of beads in 500 µl of PBS containing 1% Triton X-100 overnight at 4 o C, and unbound supernatants were collected for analysis. Beads were washed 5 times with 1 ml of PBS at 4 o C and then the adsorbed material was eluted with SDS (2%)-containing Laemmli buffer without β-mercaptoethanol for 1 h at room temperature.
Determ ination of 2-deoxyglucose (2DG ) uptake
Adipocytes were washed twice with Hepes-buffered saline solution (140 mM NaCl, 20 mM Hepes/Na, 2.5 mM MgSO4, 1 mM CaCl2 and 5 mM KCl, pH 7.4). 2DG was measured as described previously (Sweeney et al., 1999) . Briefly, cells were incubated for 15 min in the presence or absence of insulin (30 nM) and then 2DG uptake (10 µM [ 14 C]2DG, 1 µCi/ml, NEN Life Science) was measured for 3 min. Nonspecific uptake was determined in the presence of 10 µM cytochalasin B and was subtracted from all values.
G el electrophoresis and im m unoblotting
Membranes solubilized in Laemmli solution were subjected to SDS-PAGE on 8 or 10% resolving gels as described (Laemmli, 1970; Kim et al., 2004b) . Separated proteins were electrophoretically transferred to nitrocellulose membrane (Bio-Rad, Hercules, CA), blocked with 5% nonfat milk in Tris-buffered saline, and incubated with primary antibodies in TTBS (Trisbuffered saline plus 0.05% Tween 20) containing 1% non-fat milk. After overnight incubation, membranes were washed with TTBS and incubated with horseradish peroxidase-labeled protein A (for the detection of polyclonal antibodies) or horseradish peroxidaselabeled anti-mouse IgG (for the detection of monoclonal antibodies). Proteins were visualized using enhanced chemiluminescent substrate kit (NEN Life Science Products). Immunoblot intensities were quantitated by densitometry using an analytical scanning system (Molecular Dynamics Inc., Sunnyvale, CA).
Statistical analysis
Values are expressed as the mean ± SEM. Where applicable, the significance of difference was analyzed using Student's t test for unpaired data.
R esults
To develop O-GlcNAc protein modifications, we exposed the primary adipocytes isolated from epidermal fat tissue to PUGNAc (100 µM) for 0, 3, 6, and 12 h at 37 o C. The whole-cell lysates separated on SDS-PAGE were visualized through silver staining and immunoblotting with the O-GlcNAc-specific antibody CTD110.6 ( Figure 1A ). The total protein levels in whole-cell lysates were not affected by PUGNAc treatment, whereas O-GlcNAc levels determined by immunoblotting were considerably increased in wholecell lysates treated with PUGNAc for 12 h. We also treated primary adipocytes with varying concentrations of PUGNAc with fixed incubation time (12 h). The O-GlcNAc modification levels were determined by immunoblotting with CTD110.6, and the relative im-munoblot intensities against control cells were obtained ( Figure 1B) . The maximal increase appeared at 100 µM PUGNAc. No further increase in GlcNAc levels was seen in cells treated with higher PUGNAc concentrations up to 200 µM. Since the viability and m orphology of adipocytes were not affected by PUGNAc treatment (data not shown), it suggests that the treatment of 100 µM PUGNAc for 12 h successfully induces O-GlcNAc modification on proteins in primary adipocytes.
To demonstrate how the increased O-GlcNAc modification by PUGNAc correlates with glucose transport activity in rat primary adipocytes, we measured glucose uptake using radiolabeled 2DG in the adipocytes incubated with or without PUGNAc for 12 h ( Figure  2A ). The basal glucose uptake in control was not Adipocytes from rat epididymal fat tissue were isolated and incubated for indicated time (Hrs) in the presence or absence of 100 µM of PUGNAc as described in Materials and Methods. 50 µg of whole-cell lysates were separated on 8% SDS-PAGE and subjected to silver staining and immunoblotting against O-GlcNAc-specific antibody. The result shown here was representative from five independent experiments. Panel B: Adipocytes were incubated for 12 h with the indicated concentration of PUGNAc (closed circles). Adipocytes without PUGNAc treatment were used as reference immunoblot intensity. O-GlcNAc level per 50 µg of whole-cell lysate was determined by immunoblotting using CTD110.6 antibody. All data points are mean ± SEM from five independent experiments. 14 C]2DG) was measured as described in Materials and Methods. Non-specific uptake was determined in the presence of 10 µM cytochalasin B and was subtracted from all values. Data were expressed in arbitrary units where the radioactivity for basal control was set to one. Values are for basal (open column) and insulin-stimulated (closed column) adipocytes, expressed as mean ± SEM from five independent experiments. ***P 0.001 vs basal control. Panel B: Adipocytes were incubated for 0, 3, 6, and 12 h in the presence or absence of 100 µM of PUGNAc, and then 2DG was measured as described in Panel A. Then, insulin-dependent 2DG uptake was calculated in fold change where the radioactivity for basal 2DG uptake was set to one. Values for control (open column) and PUGNAc-treated (closed column) adipocytes expressed as mean ± SEM from three independent experiments. ***P 0.001 vs control.
significantly different from that in PUGNAc-treated adipocytes. Insulin stimulation (30 nM, 15 min at 37 o C) in control adipocytes increased 2DG uptake by 4.8-fold as compared with the basal state, whereas there was a significant reduction (45%) in the insulin-stimulated 2DG uptake from PUGNAc-treated adipocytes as compared to that of control (Figure 2A) , clearly indicating that PUGNAc developed insulin resistance in rat adipocytes. To confirm that the reduced 2DG uptake in PUGNAc-treated adipocytes is indeed correlated with O-GlcNAc level, we also measured 2DG uptakes from adipocytes incubated in the presence or absence of PUGNAc for various time periods such as 0, 3, 6 and 12 h ( Figure 2B ). Insulin-dependent increases of 2DG uptake in controls were consistently as high as 5-fold up to 12 h, whereas PUGNAc decreased the insulin-stimulated 2DG uptake slightly at 6 h and significantly at 12 h ( Figure 2B ), clearly suggesting that the increase of O-GlcNAc modification level in adipocytes is associated with the development of insulin resistance.
It has been known that the basal and insulin-stimulated glucose uptake in adipocytes mainly correlates with the amount of GLUT4 in the PM. Since insulin-stimulated 2DG uptake was significantly decreased by prolonged PUGNAc treatment (12 h) (Figure 2) , we next assessed whether the O-GlcNAc modification in adipocytes is associated with the impaired insulin-stimulated GLUT4 translocation. As shown in Figure 3A , total cellular GLUT4 contents were not affected by PUGNAc treatment in adipocytes. Insulin substantially (about 5-fold) increased GLUT4 translocation to the PM in control, whereas the insulin-stimulated GLUT4 translocation in PUGNActreated adipocytes was significantly reduced by 45% ( Figures 3A and B) . This indicates that O-GlcNAc modification is closely associated with the impairment of insulin-stimulated GLUT4 translocation to the PM in adipocytes. These results implicate that PUGNAc partly impairs the insulin signaling pathway responsible for the insulin-stimulated GLUT4 translocation to the PM.
It is possible that the insulin resistance by PUGNAc may result from an alteration in the insulin signaling intermediates involved in GLUT4 translocation, including IR, IRS-1, PI3K, PDK-1, and their downstream effector, Akt2 (Kanzaki and Pessin, 2003, Saltiel and Pessin, 2002) . Therefore, we immunoprecipitated OGlcNAc-m odified proteins with a specific antibody CTD110.6 as described in Materials and Methods, and we assessed the O-GlcNAc modification of insulin Since PUGNAc increased O-GlcNAc modification on IRS-1 and Akt2 as shown in Figure 4 , we also assessed the effect of PUGNAc on the insulin-stimulated phosphorylation of IRS-1 and Akt2 in adipocytes. IRS-1 or Akt2 was immunoprecipitated from adipocytes lysates, after which the phosphorylation and O-GlcNAc modification of IRS-1 and Akt2 were analyzed with the specific antibodies described in Materials and Methods ( Figure 5A and B) . Cellular insulin treatment in control drastically increased tyrosine phosphorylation of IRS-1 as compared with the basal level ( Figure 5A ). However, PUGNAc increased O-GlcNAc modification and suppressed insulin-stimulated tyrosine phosphorylation of IRS-1, suggesting that O-GlcNAc modification of IRS-1 is closely associated with the reduction of insulin-stimulated its phosphorylation. Next, we also assessed the involvement of Akt2 in impaired insulin-stimulated GLUT4 translocation by PUGNAc treatment, since phosphorylation of Akt2 has been known to play an important role in insulin-stimulated GLUT4 translocation by insulin (Saltiel and Pessin, 2002; Kanzaki and Pessin, 2003) . In a similar experiment using immunoprecipitates by anti-Akt2 antibody, the total cellular content of Akt2 was not changed by insulin or PUGNAc treatment ( Figure 5B ). Insulin treatment drastically increased the phosphorylation of Akt2 as compared with the basal level in control, whereas the insulinstimulated phosphorylation of Akt2 was drastically decreased by PUGNAc treatment. These results indicate that elevated O-GlcNAc modification inhibits insulin signaling pathways through interfering with the phosphorylation of IRS-1 and Akt2.
We also assessed whether PUGNAc increases OGlcNAc modification of GLUT4 in intracellular GLUT4 storage pools in rat adipocytes. Immunopurified GLUT4 from LDM fraction was subjected to Western blot analysis against O-GlcNAc antibody (Figure 6 ). The O-GlcNAc modification of immunopurified GLUT4 in control cells was under the detectable limit, whereas GLUT4 in PUGNAc-treated cells was substantially modified by O-GlcNAc. Since the direct effect of OGlcNAc modification on GLUT4 is not immediately 
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Akt 2 α-A B Figure 6 . Effect of PUGNAc on the O-GlcNAc modification of GLUT4 in rat adipocytes. Adipocytes were incubated for 12 h in the presence or absence of 100 µM of PUGNAc, and LDM were prepared as described in Materials and Methods. 300 µg of LDM were immunoprecipitated with normal mouse IgG (NI) or 1F8, GLUT4-specific monoclonal antibody (1F8), and immunoprecipitates were immunoblotted with polyclonal GLUT4 antibody or anti-O-GlcNAc antibody. The result shown here was representative from three independent experiments.
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clear, the possible regulatory mechanism of GLUT4 translocation by O-GlcNAc modification needs further investigation.
D iscussion
It has been proposed that increased sugar influx into the cell via HBP induces insulin resistance by increasing proteoglycan production, lipid glycosylation, and O-GlcNAc protein modification (Brownlee, 2001) . The increase of UDP-GlcNAc flux through HBP causes insulin resistance via the elevated O-GlcNAc modification on target proteins and GFAT implicates in this process (Baron et al., 1995 , Giaccari et al., 1995 Rossetti et al., 1995; Hebert et al., 1996) . In addition to increases in UDP-GlcNAc flux and GFAT activity, either activation of O-GlcNAc transferase or inhibition of O-GlcNAcase increases O-GlcNAc modification on proteins, and subsequently attenuates insulin signaling in insulin sensitive cells such as muscle and adipocytes (Haltiwanger et al., 1998; Vosseller et al., 2002; Arias et al., 2004) . However, there is as yet no convincing evidence whether the increased OGlcNAc modification of proteins by O-GlcNAcase inhibition in primary adipocytes causes substantial disturbances in insulin signaling, and if any, which insulin signaling intermediates are involved in the development of insulin resistance.
To investigate the correlation between the OGlcNAc modification and insulin resistance in rat primary adipocytes, here we used PUGNAc, a nonmetabolizable analogue of glucosamine and potent inhibitor of O-GlcNAcase (Haltiwanger et al., 1998) . Although concentration and duration of PUGNAc treatment were modified in various cells having different susceptibility, prolonged cellular treatment with PUGNAc is known to elevate O-GlcNAc modification of numerous proteins without changing N-linked glycosylation or concentration of UDP-GlcNAc and has been a useful tool for the study of cellular responses affected by O-GlcNAc modification (Mueller et al., 1998; Buren et al., 2002; Vosseller et al., 2002; Arias et al., 2004) . Since primary adipocytes isolated from epididymal fat tissues can be incubated in the general culture condition for more than 24 h without changing insulin sensitivity based on GLUT4 translocation and glucose uptake (Li et al., 2001) , we treated adipocytes with PUGNAc (100 µM) for 12 h in this study. Our experimental condition, prolonged PUGNAc treatment (6 to 12 h) to primary adipocytes successfully induced O-GlcNAc modification on proteins (Figure 1 ). This result indicates that PUGNAc treatment applied to rat primary adipocytes can be used to inhibit OGlcNAcase, resulting in a general increase in OGlcNAc modification on proteins, and is appropriate for studying the effect of O-GlcNAc modification on insulin sensitivity.
It is noteworthy that the increased O-GlcNAc modification on proteins by prolonged PUGNAc treatment significantly reduced insulin-stimulated 2DG uptake without changing basal 2DG uptake (Figure 2A and B), indicating that PUGNAc indeed induces insulin resistance in rat primary adipocytes. In previous studies, Vosseller et al. (2002) found that PUGNAcinduced GlcNAc modification of proteins is accompanied by insulin resistance in 3T3-L1 adipocytes, and Arias et al. (2004) also reported that PUGNAc decreases insulin-stimulated glucose uptake in rat skeletal muscle. Basal glucose uptake was not affected by PUGNAc in both studies. Our demonstration that insulin-stimulated glucose uptake in rat adipocytes was significantly decreased by prolonged PUGNAc treatment is consistent with these findings, and further supports that the increase of O-GlcNAc modification on proteins in rat adipocytes is closely associated with the development of insulin resistance.
Both GLUT1 and GLUT4 are expressed in insulin sensitive tissues such as adipose and muscle tissues, and they participate in the basal and insulin-stimulated glucose uptake (Handberg et al., 1992) . However, due to the relatively low abundance and insensitivity in the insulin-stimulated translocation of GLUT1, GLUT4 is the major player in the insulinstimulated glucose uptake of insulin sensitive tissues (Dean et al., 1998) . To investigate the effect of OGlcNAc modification of proteins in GLUT4 translocation, we evaluated the effect of PUGNAc on the steady-state distribution of endogenous G LUT4. PUGNAc significantly reduced insulin-stimulated GLUT4 translocation from LDM to PM without any significant effect on the basal GLUT4 levels in the PM and LDM ( Figure 3A ). This suggests that impaired insulin-stimulated GLUT4 translocation to the PM is a main cause of PUGNAc-induced insulin resistance observed in rat adipocytes.
At the molecular and cellular levels, how PUGNAc causes insulin resistance is an important question yet to be answered. It seems appropriate to suspect that the process whereby PUGNAc induces insulin resistance involves O-GlcNAc modification of insulin signaling intermediates associated with GLUT4 translocation. There is a report that the infusion of high levels of glucosamine increased O-GlcNAc modification of IRS-1, IRS-2 and PI3K in skeletal muscle (Patti et al., 1999) . More recently, Vosseller et al. (2002) demonstrated that IRS-1 and β-catenine were modified by O-GlcNAc in a PUGNAc-responsive manner in 3T3-L1 adipocytes. Even though numerous proteins modified with O-GlcNAc were increased by PUGNAc treatment (Haltiwanger et al., 1998; Gao et al., 2000; Vosseller et al., 2002; Arias et al., 2004) , their identities and functional significances were still largely unknown. Interestingly, our immunoprecipitation analysis with an O-GlcNAc specific antibody clearly demonstrated that IRS-1 and Akt2, two key intermediates in the insulin-stimulated GLUT4 translocation and glucose uptake, were O-GlcNAc modified by PUGNAc (Figure 4) . The effect of PUGNAc on OGlcNAc modification of IRS-1 and Akt2 is quite selective. PUGNAc did not modify other insulin signaling intermediates such as IR, PI3K and PDK-1 (Figure 4) . Insulin regulates GLUT4 translocation largely through the activation of IRS-1 via Tyr phosphorylation with subsequent activation/phosphorylation of its downstream effectors, such as PI3K, PDK-1, PKC-λ/ζ, and Akt2 (Saltiel and Pessin, 2002; Kanzaki and Pessin, 2003) . However, the involvement of IRS-1 and/or Akt in insulin resistance resulted from O-GlcNAc modification is controversial. In previous report, the reduced tyrosine phosphorylation of IRS-1 and -2 was observed in the glucosamine-treated rat skeletal muscle, whereas attenuation of insulin-stimulated phosphorylation of Akt was not accompanied (Patti et al., 1999) . It was also reported that the elevated OGlcNAc modification by PUGNAc induced insulin resistance in skeletal muscle independent of attenuated phosphorylation of Akt and GSK3α/β (Arias et al., 2004) . On the other hand, there is a report that PUGNAc increases O-GlcNAc modification on IRS-1, concomitant with the decreased insulin-stimulated activation of Akt in 3T3-L1 adipocytes (Vosseller et al., 2002) . However, the O-GlcNAc modification of Akt and attenuation of insulin-stimulated IRS-1 phosphorylation were not observed. The defect in Akt activation in response to excessive flux through the HBP was also suggested in 3T3-L1 adipocytes (Heart et al., 2000) . It is possible that different cells or tissues under various experimental conditions may explain controversial results. In this study, however, the treatment of PUGNAc caused drastic reductions in insulin-stimulated phosphorylation of IRS-1 and Akt2 ( Figure 5A and B), clearly suggesting that O-GlcNAc modification on IRS-1 and Akt2 is the main cause in PUGNAc-induced insulin resistance in adipocytes.
O-glycosylation and O-phosphorylation are known to participate in modification of protein interaction and regulation of signal transduction by changing the protein reaction site through mutual interaction (Griffith and Schmitz, 1999; Cheng et al., 2000) . Apparently, O-GlcNAc modification of IRS-1 by PUGNAc produces no direct effect on its Tyr phosphorylation, but it is possible that O-linked glycosylation on proximal Ser or Thr residue of IRS-1 is able to inhibit phosphorylation of Tyr residue, and that O-linked glycosylation of IRS-1 changes the conformation of its phosphorylation sites. For example, free fatty acids and cellular stress can result in increased Ser phosphorylation and reduced Tyr phosphorylation of IRS-1, thereby attenuating insulin signaling and causing insulin resistance in type 2 diabetes (Arias et al., 2004) . PKC θ phosphorylates IRS-1 at Ser residues and subsequently impairs IRS-1 Tyr phosphorylation and downstream activation of Akt2 (Kellerer et al., 1998; Lawrence et al., 1990a) . Undoubtedly more work is needed to determine the identities of OGlcNAc-modification sites and molecular events underlying attenuation of insulin-stimulated phosphorylation in the future.
In this study, PUGNAc treatment showed no effect on the expression level of GLUT4 (Figure 3) . It is consistent with the previous report that HBP-mediated insulin resistance does not result from reduced GLUT4 expression (Nelson et al., 2000) . However, we found that O-GlcNAc modification of GLUT4 was increased in the insulin-responsive glucose transporter storage pool by PUGNAc treatment (Figure 6 ). It has been also reported that O-GlcNAc modification of GLUT4 was increased in GLUT1-overexpressing muscle cells (Buse et al., 2002) . It is interesting to note the significance of this modification. A number of early studies described the functional significance of GLUT4 phosphorylation in adipocytes (Lawrence et al., 1990a; 1990b , Begum et al., 1993 . These studies showed that a relatively minor fraction of GLUT4 in adipocytes is in the phosphorylated state, and that insulin affects this steady-state level of GLUT4 phosphorylation only slightly, which leads to the conclusion that GLUT4 phosphorylation may not play a significant role in insulin-induced GLUT4 recruitment (Lawrence et al., 1990b; Begum et al., 1993) . Nevertheless, the possible reciprocal regulation between GLUT4 phosphorylation and O-glycosylation needs further investigation to clarify the insulin resistance mechanism.
In conclusion, O-GlcNAc modification as a new regulatory signal is an important process involved in glucose uptake and insulin signaling with the development of insulin resistance in rat adipocytes. Our results clearly show that the treatment of PUGNAc is directly correlated with the elevation of O-GlcNAc protein modifications and the development of insulin resistance in rat primary adipocytes. It is also clear in our data that the elevated O-GlcNAc modification of IRS-1 and Akt2 by PUGNAc is closely associated with the reduction of insulin-stimulated phosphorylations of IRS-1 and Akt2. Here, we suggest that the increase of O-GlcNAc modifications on insulin signal pathway intermediates such as IRS-1 and Akt2, and the reduction in insulin-stimulated phosphorylation of IRS-1 and Akt2 are associated with the development of insulin resistance in PUGNAc-treated rat primary adipocytes.
